atenolol has been researched along with Genetic Predisposition in 3 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These findings suggest that selected signals from hypertension genome-wide association studies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring." | 5.16 | Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. ( Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hou, W; Johnson, JA; Langaee, TY; McDonough, CW; Turner, ST; Wang, Z, 2012) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrythmogenic disease characterized by exercise--or stress--induced ventricular tachyarrythmias, syncope, or sudden death, usually in the pediatric age group." | 1.35 | Catecholaminergic polymorphic ventricular tachycardia in a child: a case report. ( De Wolf, D; Garabedian, L; Panzer, J; Verryckt, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papp, AC | 1 |
| Pinsonneault, JK | 1 |
| Wang, D | 1 |
| Newman, LC | 1 |
| Gong, Y | 2 |
| Johnson, JA | 2 |
| Pepine, CJ | 1 |
| Kumari, M | 1 |
| Hingorani, AD | 1 |
| Talmud, PJ | 1 |
| Shah, S | 1 |
| Humphries, SE | 1 |
| Sadee, W | 1 |
| McDonough, CW | 1 |
| Wang, Z | 1 |
| Hou, W | 1 |
| Cooper-DeHoff, RM | 1 |
| Langaee, TY | 1 |
| Beitelshees, AL | 1 |
| Chapman, AB | 1 |
| Gums, JG | 1 |
| Bailey, KR | 1 |
| Boerwinkle, E | 1 |
| Turner, ST | 1 |
| Garabedian, L | 1 |
| Verryckt, A | 1 |
| Panzer, J | 1 |
| De Wolf, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
1 trial available for atenolol and Genetic Predisposition
| Article | Year |
|---|---|
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Topics: Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Female; Genetic Loci; Genetic Predi | 2012 |
2 other studies available for atenolol and Genetic Predisposition
| Article | Year |
|---|---|
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
Topics: Adult; Alleles; Atenolol; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, | 2012 |
Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
Topics: Anti-Arrhythmia Agents; Atenolol; Catecholamines; Child, Preschool; Diagnosis, Differential; Exercis | 2008 |